Heatwurx (NASDAQ:PCSA) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Heatwurx (NASDAQ:PCSA) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Heatwurx in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Heatwurx presently has a consensus rating of “Hold” and a consensus target price of $25.00.

Heatwurx Price Performance

Shares of NASDAQ:PCSA opened at $2.22 on Friday. The stock has a market cap of $5.04 million, a price-to-earnings ratio of -0.07 and a beta of 1.14. The company has a 50 day moving average of $3.47 and a 200-day moving average of $5.46. Heatwurx has a one year low of $2.05 and a one year high of $19.64.

About Heatwurx

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.